Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

被引：28
|
作者：
Zhang, Yiyin [1 ,2 ,3 ,4 ]
Yang, Chao [1 ,2 ,3 ,4 ]
Cheng, He [1 ,2 ,3 ,4 ]
Fan, Zhiyao [1 ,2 ,3 ,4 ]
Huang, Qiuyi [1 ,2 ,3 ,4 ]
Lu, Yu [1 ,2 ,3 ,4 ]
Fan, Kun [1 ,2 ,3 ,4 ]
Luo, Guopei [1 ,2 ,3 ,4 ]
Jin, Kaizhou [1 ,2 ,3 ,4 ]
Wang, Zhengshi [1 ,2 ,3 ,4 ]
Liu, Chen [1 ,2 ,3 ,4 ]
Yu, Xianjun [1 ,2 ,3 ,4 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, 270 DongAn Rd, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, 270 DongAn Rd, Shanghai 200032, Peoples R China
[3] Shanghai Pancreat Canc Inst, 270 DongAn Rd, Shanghai 200032, Peoples R China
[4] Fudan Univ, Pancreat Canc Inst, 270 DongAn Rd, Shanghai 200032, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2018年 / 11卷
基金：
中国国家自然科学基金;
关键词：
Pancreatic ductal adenocarcinoma; Novel regimens; Biomarkers; Combination therapies; GEMCITABINE PLUS PLACEBO; PHASE-II TRIAL; ALGENPANTUCEL-L IMMUNOTHERAPY; STANDARD ADJUVANT THERAPY; DOUBLE-BLIND; MESENCHYMAL TRANSITION; E-CADHERIN; RESECTABLE ADENOCARCINOMA; PREOPERATIVE GEMCITABINE; IONIZING-RADIATION;
D O I：
10.1186/s13045-017-0551-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation) therapy is the main treatment approach. However, gemcitabine-and 5-fluorouracil-based therapies did not present satisfying outcomes. Novel regimens targeting pancreatic cancer cells, the tumor microenvironment, and immunosuppression are emerging. Biomarkers concerning the treatment outcome and patient selection are being discovered in preclinical or clinical studies. Combination therapies of classic chemotherapeutic drugs and novel agents or novel therapeutic combinations might bring hope to the dismal prognosis for PDAC patients.
引用
收藏
页数：17
相关论文
共 50 条
  • [31] Metastatic Pancreatic Adenocarcinoma: Current Standards, Future Directions
    Duffy, Austin
    Kummar, Shivaani
    AMERICAN JOURNAL OF THERAPEUTICS, 2010, 17 (01) : 79 - 85
  • [32] Current Management and Future Directions in Metastatic Pancreatic Adenocarcinoma
    Varghese, Anna M.
    Lowery, Maeve A.
    Yu, Kenneth H.
    O'Reilly, Eileen M.
    CANCER, 2016, 122 (24) : 3765 - 3775
  • [33] PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma
    Chapin, William J.
    Reiss, Kim A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2022, 36 (05) : 1019 - 1032
  • [34] A novel RAS inhibitor for pancreatic ductal adenocarcinoma.
    Arshad, Tariq
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16263 - E16263
  • [35] Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma
    Ali, Ahmad
    Chianese, Ugo
    Papulino, Chiara
    Toraldo, Antonella
    Abakar, Mawada Elmagboul Abdalla
    Passaro, Eugenia
    Cennamo, Rosario
    Del Gaudio, Nunzio
    Altucci, Lucia
    Benedetti, Rosaria
    CANCERS, 2022, 14 (15)
  • [36] Splice variants as novel targets in pancreatic ductal adenocarcinoma
    Jun Wang
    Laurent Dumartin
    Andrea Mafficini
    Pinar Ulug
    Ajanthah Sangaralingam
    Namaa Audi Alamiry
    Tomasz P. Radon
    Roberto Salvia
    Rita T. Lawlor
    Nicholas R. Lemoine
    Aldo Scarpa
    Claude Chelala
    Tatjana Crnogorac-Jurcevic
    Scientific Reports, 7
  • [37] Splice variants as novel targets in pancreatic ductal adenocarcinoma
    Wang, Jun
    Dumartin, Laurent
    Mafficini, Andrea
    Ulug, Pinar
    Sangaralingam, Ajanthah
    Alamiry, Namaa Audi
    Radon, Tomasz P.
    Salvia, Roberto
    Lawlor, Rita T.
    Lemoine, Nicholas R.
    Scarpa, Aldo
    Chelala, Claude
    Crnogorac-Jurcevic, Tatjana
    SCIENTIFIC REPORTS, 2017, 7
  • [38] Prolactin Receptor, a Novel Target for Pancreatic Ductal Adenocarcinoma
    Dandawate, P.
    Kaushik, G.
    Subramaniam, D.
    Ghosh, C.
    Choudhury, S.
    Standing, D.
    Ramamoorthy, P.
    Manzardo, A.
    Sayed, A.
    Banerjee, T.
    Santra, S.
    Butler, M.
    Padhye, S. B.
    Baranda, J.
    Kasi, A.
    Sun, W.
    Tawfik, O.
    Coppola, D.
    Malafa, M.
    Umar, S.
    Soares, M. J.
    Saha, S.
    Weir, S. J.
    Dhar, A.
    Jensen, R. A.
    Thomas, S. M.
    Anant, S.
    PANCREAS, 2018, 47 (10) : 1382 - 1382
  • [39] Novel therapeutics and future directions for refractory immune thrombocytopenia
    Al-Samkari, Hanny
    Neufeld, Ellis J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (01) : 65 - 78
  • [40] Pancreatic ductal adenocarcinoma
    Gallmeier, E.
    Gress, T. M.
    INTERNIST, 2018, 59 (08): : 805 - 822
12345